Thermo Fisher Scientific announce expansion of cell culture media manufacturing site
The expansion of Thermo Fisher Scientific’s Grand Island, New York cell culture media manufacturing site offers increased redundant capacity in support of vaccine and biologic therapy development and manufacturing.
Thermo Fisher Scientific have announced a USD $76 million investment for the expansion of their cell culture media manufacturing site in Grand Island, New York for increased production of critical raw materials for use in the development and manufacturing of vaccines and other biologic therapies.
As global demand for cell culture media increases with the rise in new vaccine and biologics manufacturing, Thermo Fisher Scientific has invested in the expansion of its dry powder media manufacturing facility to meet this demand. The expansion of the site will provide redundant capacity in support of the global supply of media and extend capabilities for the commercial development and manufacturing of vaccines. The Grand Island expansion constitutes a part of the UDS $650 million multi-year expansion Thermo Fisher announced in 2021 in a move to ensure reliable and scalable bioprocessing production capacity for medicine including vaccines against COVID-19.
Kate Torchilin, President, biologicals and chemicals at Thermo Fisher Scientific, stated: “Our expanded Grand Island site represents a significant milestone in our investment to double our total manufacturing capacity by the end of 2023… With the harmonized capabilities of our global manufacturing sites that enable us to prove equivalency in manufacturing, we’re able to support current demand while priming for future growth and continuously enhancing our customer experience globally.”
The expansion encompasses over 45,000 square feet of Animal Origin Free manufacturing space, including Thermo Fisher’s Advanced Granulation Technology format and other dry powder media products. The development and production of biotherapeutics and vaccines will be accelerated in a rapid and reliable manner through the additional site capacity, offering biotechnology deveopers and CDMOs the ability to increase their footprint in the realm of innovative biologics, biosimilars and other therapeutics. In addition to increased manufacturing space, the Grand Island site expansion will add approximately 100 team members in roles ranging from research and development, operations, manufacturing, HR and engineering.
Congressman Brian Higgins commented: “The story of Thermo Fisher’s presence on Grand Island speaks to the longstanding positive reputation of the biomedical research community in Western New York… Now employing over 1,600, I am proud to share in the celebration of Thermo Fisher’s continued investments and commitment to the community in Western New York.”
Source: Thermo Fisher press release Thermo Fisher Scientific Expands Cell Culture Media Manufacturing Site in Grand Island, New York
Related News
-
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Women in Pharma: Minding the Gap at Pharmapack 2024
2024 marks the first year Pharmapack will host a Diversity track dedicated to bridging the gap within the pharmaceutical packaging and drug delivery sector. The track includes a panel discussion on 'Enabling Diversity in the Workplace,' focused... -
News Pharmapack Awards 2024 - Celebrating Packaging and Drug Delivery Innovation
The 2024 Pharmapack Innovation Awards ceremony celebrated the best in pharmaceutical packaging and drug delivery innovation at all levels. The awards were held on January 24, 2024 at the Paris Expo Porte de Versailles. -
News 2024 Pharma Industry Trends Outlook: Collaboration, Market Maturity, and Digital Futures
The annual CPHI Online 2024 Pharma Trends Outlook, in partnership with Arvato Systems, identifies 12 key industry trends shaping the life sciences industry in the coming year. -
News New Novo Nordisk AI hub for drug discovery to open in London, UK
Danish pharmaceutical giant Novo Nordisk will be opening an AI-based research facility in the heart of London to advance drug discovery operations. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Women in Pharma: Looking back on 2023 and moving forward to 2024
In this monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News CPHI Barcelona 2023: Partnering for Success – Managing Outsourcing Relationships to Optimise Manufacturing Operations
During CPHI Barcelona 2023, insightful content sessions offered attendees the chance to explore trending topics with expert speakers and panellists. Here, we summarise what the pharma industry and supply chain are talking about the most.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance